Not Disclosed

Drug Name: Not Disclosed
Company: Prosetta Biosciences
Location: US-California
Website: https://www.prosetta.com/als-program/
Drug Type: Small Molecule
Conditions: ALS
Mechanism Type: TDP-43 relocalization
Mechanism: This approach aims to reduce motor neuron toxicity in ALS by pushing TDP-43 back into the nucleus.
U.S. Status for ALS: Preclinical

Last updated February 15th, 2018

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail